Who Exports Iron from India — 943 Suppliers Behind a $487.6M Market
India's iron export market is supplied by 943 active exporters who collectively shipped $487.6M across 14,943 shipments. ZYDUS LIFESCIENCES LIMITED leads with a 27.4% market share, followed by UNICHEM LABORATORIES LIMITED and AMNEAL PHARMACEUTICALS PRIVATE LIMITED. The top 5 suppliers together control 65.6% of total export value, reflecting a concentrated market structure.
Top Iron Exporters from India — Ranked by Export Value
ZYDUS LIFESCIENCES LIMITED is the leading iron exporter from India, holding a 27.4% share of the $487.6M market across 14,943 shipments from 943 exporters. The top 5 suppliers — ZYDUS LIFESCIENCES LIMITED, UNICHEM LABORATORIES LIMITED, AMNEAL PHARMACEUTICALS PRIVATE LIMITED, INTAS PHARMACEUTICALS LIMITED, AUROBINDO PHARMA LTD — collectively control 65.6% of total export value, indicating a moderately concentrated market. Individual shares are: ZYDUS LIFESCIENCES LIMITED (27.4%), UNICHEM LABORATORIES LIMITED (24.2%), AMNEAL PHARMACEUTICALS PRIVATE LIMITED (7.9%), INTAS PHARMACEUTICALS LIMITED (3.4%), AUROBINDO PHARMA LTD (2.8%).
Top Iron Exporters from India
Ranked by export value · 943 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | ZYDUS LIFESCIENCES LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T] | $133.5M | 4 | 27.4% |
| 2 | UNICHEM LABORATORIES LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T] | $118.2M | 3 | 24.2% |
| 3 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T] | $38.4M | 1 | 7.9% |
| 4 | INTAS PHARMACEUTICALS LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T]PHARMA DRUGS & MEDI SPIRONOLACTONE 50MG1 | $16.5M | 18 | 3.4% |
| 5 | AUROBINDO PHARMA LTD SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T] | $13.6M | 1 | 2.8% |
| 6 | MYLAN LABORATORIES LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T] | $12.0M | 6 | 2.5% |
| 7 | KAUSIKH THERAPEUTICS PRIVATE LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T] | $11.7M | 2 | 2.4% |
| 8 | EMCURE PHARMACEUTICALS LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T]PHARMACEUTICALS PRODUCTS LIKFERR 100 MG INJ 5X5 ML AMP | $10.6M | 43 | 2.2% |
| 9 | STRIDES PHARMA SCIENCE LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T]VITAFER FORTE SYRUP OF IRON AND FOLIC AC | $9.4M | 3 | 1.9% |
| 10 | RUBICON RESEARCH PRIVATE LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T] | $9.1M | 1 | 1.9% |
| 11 | SWATI SPENTOSE PRIVATE LIMITED JELMIRON CAPSULES 9000 BOTTELS X90=8100AVIRON TABLETS 500MGIRON SUCROSE COMPLEX | $8.2M | 1 | 1.7% |
| 12 | AUROBINDO PHARMA LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T] | $7.2M | 1 | 1.5% |
| 13 | CADILA HEALTHCARE LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T]VITAFER FORTE SYRUP OF IRON AND FOLIC AC | $5.1M | 1 | 1.0% |
| 14 | STRIDES ALATHUR PRIVATE LIMITED SPIRONOLACTONE TABLETS 50MG 1X500 PACKS)BUSPIRONE HCL TABLETS USP 15MG [8628 BTLX 500T]VITAFER FORTE SYRUP OF IRON AND FOLIC AC | $4.6M | 1 | 0.9% |
| 15 | PIRAMAL PHARMA LIMITED PHARMA DRUGS & MEDI SPIRONOLACTONE 50MG1PHARMA DRUGS & MEDI SPIRONOLACTONE 25MG1BUSPIRONE HYDROCHLORIDE TABLETS[5MG]121 | $3.8M | 3 | 0.8% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Iron exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Zydus Lifesciences Limited | Warning Letter (August 20 | Not Listed | Not Listed | Not verified | FDA issued a warning letter citing CGMP violations at the Vadodara facility. |
| Aurobindo Pharma Limited | Warning Letter (June 2019 | Yes, multiple produc | Not Listed | Not verified | FDA issued a warning letter for CGMP deviations; WHO prequalified multiple produ |
| Emcure Pharmaceuticals Limited | Approved | Yes, product prequal | Not Listed | 1 | FDA approved ANDA 210036; WHO prequalified Dolutegravir Tablet 50mg. (extranet.w |
| Mylan Laboratories Limited | Approved | Yes, multiple produc | Not Listed | Multiple | FDA approved multiple ANDAs; WHO prequalified several products. (extranet.who.in |
| Strides Pharma Science Limited | Approved | Yes, product prequal | Not Listed | Multiple | FDA approved multiple ANDAs; WHO prequalified Emtricitabine/Tenofovir disoproxil |
| Laurus Labs Limited | Approved | Yes, product prequal | Not Listed | Multiple | FDA approved multiple ANDAs; WHO prequalified Emtricitabine/Tenofovir disoproxil |
| Macleods Pharmaceuticals Ltd | Approved | Yes, product prequal | Not Listed | Multiple | FDA approved multiple ANDAs; WHO prequalified Dolutegravir (sodium) Tablet. (ext |
| Hetero Labs Ltd | Approved | Yes, product prequal | Not Listed | Multiple | FDA approved multiple ANDAs; WHO prequalified Abacavir (sulfate)/Lamivudine Tabl |
TransData Nexus reviewed the regulatory standing of 8 leading Iron exporters from India. 6 hold US FDA facility approvals, 7 maintain WHO-GMP certification, and 0 are EU GMP compliant. 2 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Iron sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. This prominence is supported by a robust ecosystem of pharmaceutical companies specializing in active pharmaceutical ingredients (APIs) and intermediates. Notable firms such as A.R. Life Sciences and Hy-Gro Chemicals are headquartered here, focusing on the development and manufacturing of APIs and specialty fine chemicals. The city's infrastructure, including the Hyderabad Pharma City project, further enhances its capacity for bulk drug manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is recognized as a significant hub for pharmaceutical formulations. Gujarat's pharmaceutical industry holds a 33% share in drug manufacturing and a 28% share in drug exports within India. Vadodara, in particular, hosts major pharmaceutical companies like Alembic Pharmaceuticals, which specializes in formulations for therapeutic areas such as cardiology and infectious diseases. The region's focus on formulations complements Hyderabad's bulk drug production, creating a comprehensive supply chain for iron-related pharmaceutical products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to global markets. Companies like Formel Labs, with facilities in both Mumbai and Hyderabad, leverage this strategic location to ensure efficient distribution and export of their products. The region's well-established logistics and regulatory infrastructure support the seamless export of iron-related pharmaceutical products.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a pharmaceutical manufacturing hub, primarily due to favorable tax incentives offered by the government. This zone attracts numerous pharmaceutical companies seeking cost-effective production solutions. While not directly linked to iron-related pharmaceutical products, the region's manufacturing capabilities contribute to the overall pharmaceutical supply chain in India.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 65.6% of the market, it's advisable to diversify the supplier base to mitigate risks associated with over-reliance on a few key players.
- Leverage Regional Strengths: Utilize Hyderabad's expertise in bulk drug production for sourcing APIs and intermediates, while engaging with Ahmedabad-Vadodara-based companies for finished formulations.
- Optimize Export Logistics: Collaborate with firms in the Mumbai-Thane-Raigad region to streamline export processes, taking advantage of the established logistics infrastructure.
- Monitor Regulatory Compliance: Ensure that all suppliers adhere to international regulatory standards, such as those set by the FDA, EMA, and WHO, to maintain product quality and facilitate smooth market entry.
By strategically engaging with these pharmaceutical clusters and adhering to the outlined recommendations, TransData Nexus can enhance its supply chain resilience and capitalize on India's robust pharmaceutical manufacturing capabilities.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Iron exporters from India
Zydus Lifesciences Limited — Zydus Lifesciences to acquire Amplitude Surgical for €300 million
Zydus Lifesciences announced plans to acquire France-based Amplitude Surgical, a company specializing in lower limb orthopaedics, for approximately €300 million. Amplitude reported sales of €106 million in FY24 with an EBITDA of €27.1 million, reflecting a 25.5% margin. - IMPACT: This acquisition diversifies Zydus's portfolio into medical devices, potentially impacting its focus on iron product exports.
Impact: This acquisition diversifies Zydus's portfolio into medical devices, potentially impacting its focus on iron product exports.
Common Questions — Iron Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which iron supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, ZYDUS LIFESCIENCES LIMITED leads with 432 recorded shipments worth $133.5M. UNICHEM LABORATORIES LIMITED (644 shipments) and AMNEAL PHARMACEUTICALS PRIVATE LIMITED (375 shipments) are also established high-volume exporters.
Q How many iron manufacturers are there in India?
India has 943 active iron exporters with a combined export market of $487.6M across 14,943 shipments to 174 countries. The top 5 suppliers hold 65.6% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for iron from India?
Average FOB unit price: $6.94 per unit, ranging from $0.00 to $5929.79. Average shipment value: $32.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 943 verified Indian exporters of Iron ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 14,943 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 174 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
14,943 Verified Shipments
943 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists